Parkinson Disease (PD)NCT07115563
Daily Amino Acid Supplementation for People With Parkinson's Disease
A study testing Targeted Amino Acid Supplement in people with Parkinson Disease (PD), run by Cristina Colon-Semenza at 2 sites in United States.
Trial summary
The goal of this clinical trial is to learn if a tailored amino acid supplement works to help adults living with Parkinson's disease to improve nutrition, metabolic function, body composition, and physical and mental function. Read more about this study
- Who is it for?
- Ages 50 to 90 years
- Conditions the study is for
- Parkinson Disease (PD)
- What is being tested?
- Targeted Amino Acid Supplement
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 30 participants
- Where
- 2 sitesUnited States
- Study dates
- 31 Oct 2025to Nov 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Inclusionary Criteria:
- Male and Females.
- 50-80 Years.
- Previous diagnosis of idiopathic Parkinson's Disease by patient report.
- Use of dopamine replacement medication (e.g. levodopa) for at least 2 years.
- On a stable dose of dopamine replacement medication for at least 3 months with no plans for change in the next two months.
Exclusionary criteria
- Apparent cognitive impairment as determined by phone screening (Telephone Interview for Cognitive Status <29).
- Diagnosis of Parkinsonism or atypical Parkinson's Disease.
- Prescription of Dopamine antagonist.
- Any unstable medical condition.
- Use of Deep Brain Stimulation.
- Gastric or Bowel resection surgery.
- Contraindications to blood draw.
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
United States2 sites, 2 recruiting
- Recruiting
UConn Health
Farmington, Connecticut, 06030
Carlos Rehbein, MS, 860-486-1121, carlos.rehbein@uconn.edu
Bernardo Rodrigues, MD, PhD
- Recruiting
University of Connecticut
Storrs, Connecticut, 06269
Jacob Earp, MS, 860-486-2671, jacob.earp@uconn.edu
Carlos Rehbein, carlos.rehbein@uconn.edu
About this study
Official title: Effects of Targeted Amino Acid Supplementation for People With Parkinson's Disease on Amino Acid Profiles and Health Related Markers
The goal of this clinical trial is to learn if a tailored amino acid supplement works to help adults living with Parkinson's disease to improve nutrition, metabolic function, body composition, and physical and mental function. The main questions it aims to answer are:
Does the tailored amino acid supplement increase essential amino acids (nutritional status)?
Read more
Does the tailored amino acid supplement increase an antioxidant (complex amino acid) and decrease an amino acid associated with oxidative stress?
Does the tailored amino acid supplement improve physical and mental health compared to a placebo supplement?
Researchers will compare the tailored amino acid supplement to a placebo (a look-alike substance that contains no active ingredients) to see if the tailored amino acid supplements work to support health for people with Parkinson's disease.
Participants will:
Take the tailored amino acid supplement or a placebo every day for 6 months, visit the lab at baseline, after 3 months, and after 6 months for fasting blood draws, body composition assessment, and physical and mental health testing and keep a diary of their food intake and supplement intake.
Read the detailed description
The purpose of this trial is to determine the effects of a targeted amino acid supplement (T-AA) specifically designed to correct characteristic amino acid deficiencies and meet the unique nutritional needs of people with Parkinson's disease (PD) on 1) plasma amino acid (AA) bioavailability, 2) metabolic function, 3) body composition, 4) physical function and 5) self-reported outcomes.
- Conditions
- Parkinson Disease (PD)
- Being tested
- Targeted Amino Acid Supplement, Control (placebo)
- Keywords
- Nutrition, Parkinson's disease, Amino acid supplements
- Medical subject headings
- Parkinson Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Targeted Amino Acid SupplementDietary supplement
Blend of the essential amino acids (Leucine \& Tryptophan), a conditionally essential amino acids (Arginine \& Taurine), and non-essential amino acids (Glutamate \& Tyrosine) designed to meet the unique nutritional needs of people with Parkinson's disease (PD).
Control (placebo)Dietary supplement
The inert amino acid (alanine) will serve as an isonitrogenous control.
| Study group | Role | What they receive |
|---|---|---|
| Control | Placebo comparator | The inert amino acid (alanine) will serve as an isonitrogenous control. Receives: Dietary Supplement: Control (placebo) |
| Targeted Amino Acid Supplement | Experimental | Blend of the essential amino acids (Leucine \& Tryptophan), a conditionally essential amino acids (Arginine \& Taurine), and non-essential amino acids (Glutamate \& Tyrosine) designed to meet the unique nutritional needs of people with Parkinson's disease (PD). Receives: Dietary Supplement: Targeted Amino Acid Supplement |
What is being measured
The primary outcome is the main question the study is designed to answer.
Amino Acid bioavailability (Lysine, Tryptophan, Arginine, Glutamate, Leucine, Taurine, Glutathione)
Circulating amino acid concentrations will be measured from blood samples using high performance liquid chromatography using a solid phase column specifically designed to test amino acids (e.g. 00F-4435-E0, Phenomenex, USA) along with appropriate column guards (e.g. AJ0-7597 \& KJ0-4282, Phenomenex, USA) and liquid phases. This analysis will be performed at the Laboratory of Mass Spectroscopy and Omics Analysis.
Measured: Baseline, 3 months, and 6 months
Oxidative stress
Oxidative stress will be measured using a total antioxidant power test (e.g. ab65329, ABCAM, USA). It is a quantitative bioassay and will be performed using the laboratory facilities.
Measured: Baseline, 3 months, 6 months
Oxidative stress
Oxidative stress will be assessed with reduced/oxidized glutathione assays (e.g. ab138881, ABCAM, USA). It is a quantitative bioassay and will be assessed using laboratory facilities.
Measured: Baseline, 3 months, and 6 months
Secondary outcomes (19)
Body composition: Bioelectrical impedance
Body composition will be assessed using a multi-spectral bioelectrical impedance (Mediana i55, Mediana, South Korea). During this test participants will clean their feet and hands using a sanitary wipe and then stand barefoot on the impedance machine while holding two electrodes. Then a small and imperceivable multi-spectral electrical current will be sent between limbs which the machine will use to estimate the fat content and distribution based on the resistance (i.e., impedance) of this current.
Measured: Baseline, 3 months, 6 months
Body composition: Ultrasound & Shear Wave Elastography (Tissue Organization & Fibrosis)
A trained (>20 hr. logged research scanning) ultrasound researcher will use an ultrasound (ACUSON Sequoia, Siemens Healthineers, USA) to assess muscle thickness of the primary knee extensors (quadriceps femoris) and the plantar flexors (gastrocnemius and soleus) as well as their tendons. Longitudinal panoramic 2D ultrasound will be used to measure muscle fascicle length and angle of each muscle. To assess tissue composition of these muscles shear-wave elastography will be used to measure localized muscle stiffness based on propagation of a concentrated acoustic shear (push-pull) wave applied to the center of the muscle.
Measured: Baseline, 3 months, 6 months
Physical function: Physical activity
Participants will be sent a research-grade activity monitor, Actigraph GT9X device, in the standard mail at their residence. After receiving the device, participants will engage in a telephone or virtual meeting with a research assistant to learn how to use the device. (approximately 30-40 minutes). Participants will be asked to wear the activity monitor for 7 days prior to the first baseline visit. They will be asked to continuously wear the device on their wrist for the 7 days. Participants will return the device in a pre-paid envelope. The same procedure will occur at the conclusion of the intervention for a post-intervention assessment.
Measured: 7 days prior to baseline visit and 7 days after the 6-month visit
Physical function: Balance (Mini Balance Evaluation System Test)
This test assesses balance impairments across 14 items consisting of dynamic balance, anticipatory postural adjustments, reactive postural control, sensory orientation and dynamic gait. The total score ranges from 0 to 28, with each item scored on a scale from 0 to 2 with higher scores indicating better balance.
Measured: baseline, 3 months, 6 months
Physical function: Gait speed (4-meter walking test)
This physical test measures the speed at which a person can walk for 4 meters which is related to overall functional ability. The patient is asked to walk at normal speed for 4 meters, while the evaluator records the time required for it. The gait speed is calculated dividing the distance (4m) by the time completed by the participant. The fastest of 2 trials is then recorded.
Measured: baseline, 3 months, 6 months
Physical function: Gait speed (10-meter walk test)
This test measures the speed at which a person can walk for 10 meters. The participant will walk for 10 meters, divided by 2 initial meters of acceleration and 2 final meters for deacceleration. The walking speed during the central 6 meters is then recorded.
Measured: baseline, 3 months, 6 months
Physical function: Functional lower extremity strength (5 Times Sit to Stand Test)
The Five Times Sit to Stand Test is a physical test for measuring functional strength in the lower limbs. For this test, the participant must stand up and sit down on an armless chair with their arms crossed on their chest as fast as possible 5 times. A practice trial is permitted before the test trial.
Measured: baseline, 3 months, 6 months
Physical function: Grip strength
Bilateral grip strength will be assessed with the use of a handheld dynamometer. For this test the participant must be seated on a chair, with the assessed limb at 90º of elbow flexion and holding the dynamometer in a neutral wrist position. Two sub-maximal trials at 50% and 70% of the Maximal voluntary Isometric grip contraction will be performed as a warmup. Then, 3 maximal trials separated by 1 minute of rest will be performed. If there is a 5% or bigger difference in strength for any trial, a fourth attempt must be completed. The highest value obtained for each limb is recorded.
Measured: baseline, 3 months, 6 months
Physical function: Maximal voluntary isometric contraction
In these tests participants will be seated in an isometric dynamometer (Biodex System 4, Biodex, USA) with their body and dynamometers positioned according to manufacturer instructions. In these positions participants will perform three submaximal practice isometric contractions (~25%, 50%, and 75% maximal effort) and then 5 maximal effect isometric contractions with each contraction separated 1 min of rest.
Measured: baseline, 3 months, 6 months
Self-reported outcome: Quality of Life (Parkinson Disease Questionnaire-39)
This questionnaire assesses the difficulties that people with PD experience across 8 dimensions of daily living; Activities of Daily Living, Attention \& Working Memory, Cognition, Communication, Depression, Functional Mobility, Quality of Life, Social Relationships and Social Support. The score ranges from 0-100 with higher scores indicating worse quality of life.
Measured: baseline, 3 months, 6 months
Self-reported outcome: Fatigue (Parkinson's Fatigue Scale)
This is a 16-Item patient-rated questionnaire that quantifies fatigue in people with PD. The scores range from 16 to 80 with higher scores indicating higher levels of fatigue.
Measured: baseline, 3 months, 6 months
Self-reported outcome: Sleep (Scales for Outcomes in Parkinson disease- Sleep, nighttime sleep)
This is a patient-reported questionnaire that assess nighttime sleep across 5 items in patients with Parkinson's disease. The score ranges from 0-15 with higher scores indicating worse sleep.
Measured: baseline, 3 months, 6 months
Self-reported outcome: Sleep (Scales for Outcomes in Parkinson disease- Sleep, daytime sleepiness)
This is a patient-reported questionnaire that assess daytime sleepiness across 6 items in patients with Parkinson's disease. The score ranges from 0-18 with higher scores indicating more daytime sleepiness.
Measured: Baseline, 3 months, 6 months
Self-reported outcome: Sleep (Scales for Outcomes in PD-Sleep, Global sleep quality)
This is a patient-reported questionnaire that assess the individual's global assessment of nighttime sleep with one item in patients with Parkinson disease. The score ranges from 0-6 with higher scores indicating worse global sleep quality.
Measured: Baseline, 3 months, 6 months
Self-reported outcome: Mood (Profile of Mood State)
This an assessment of current mood state. It is a 40-item self-report survey that evaluates the degree to which a participant is feeling a selected emotion at the moment. The score ranges from -30 to 200 with higher scores indicating worse mood.
Measured: baseline, 3 months, 6 months
Self-reported outcome: Anxiety (Beck Anxiety Inventory)
This is an assessment of somatic and cognitive symptoms of anxiety. It consists of 21 items in the form of self-reported questionnaire. The score ranges from 0-63 with higher scores indicating higher levels of anxiety.
Measured: baseline, 3 months, 6 months
Self-reported outcome: Motivation (Behavioral Regulation in Exercise Questionnaire-2)
This is the most used measure of motivators for exercise. It is a 19-item survey that evaluates the stages of motivation to exercise. This includes amotivation, external regulation, introjected regulation, identified regulation, and intrinsic regulation. The score ranges from -24 to +20 with higher scores indicating increased motivation.
Measured: baseline, 3 months, 6 months
Self-reported outcome: Depression (Geriatric Depression Scale-short form)
This is a 15-item self-report measure of depression in older adults. Scores range from 0-15 with higher scores indicating more severe depression.
Measured: baseline, 3 months, 6 months
Insulin sensitivity
Blood drawn will be used to analyze blood glucose. A test strip will be inserted into a glucose meter and a small sample of blood will be applied. The blood glucose level will be recorded.
Measured: baseline, 3 months, 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Aug 2025
- Study start31 Oct 2025
- Primary completionSep 2027 (estimated)
- Study completionNov 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Parkinson Disease (PD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cristina Colon-Semenza
- Sponsor type
- University, hospital or other
- Collaborators
- United States Department of Agriculture (USDA)
- Responsible party
- Sponsor-investigator, Cristina Colon-Semenza, University of Connecticut
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07115563
- Sponsor's protocol ID
- 25-02-219-910
- Other IDs
- B2025-0194
- Status last verified
- Aug 2026
- First submitted
- 29 Jul 2025
- Last updated
- 13 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: IPD used in the results publication
Publications
Earp JE, Colon-Semenza C, LoBuono DL. Considerations for developing a targeted amino acid supplement for people with Parkinson's disease that promotes health while accounting for pathophysiology and medication interference. Nutr Rev. 2023 Jul 10;81(8):1063-1076. doi: 10.1093/nutrit/nuad008.
PubMed 36809398
Study at a glance
From the registry record, last updated by the sponsor on 13 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Targeted Amino Acid Supplementation for People With Parkinson's Disease on Amino Acid Profiles and Health Related Markers
- ClinicalTrials.gov ID
- NCT07115563
- Acronym / sponsor ID
- 25-02-219-910
- Conditions
- Parkinson Disease (PD)
- Keywords
- Nutrition, Parkinson's disease, Amino acid supplements
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Cristina Colon-SemenzaUniversity, hospital or other
- Collaborators
- United States Department of Agriculture (USDA)
- Study start
- 31 Oct 2025 (actual)
- Primary completion
- Sep 2027 (estimated)
- Study completion
- Nov 2027 (estimated)
- First posted
- 11 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn if a tailored amino acid supplement works to help adults living with Parkinson's disease to improve nutrition, metabolic function, body composition, and physical and mental function. The main questions it aims to answer are:
Does the tailored amino acid supplement increase essential amino acids (nutritional status)?
Does the tailored amino acid supplement increase an antioxidant (complex amino acid) and decrease an amino acid associated with oxidative stress?
Does the tailored amino acid supplement improve physical and mental health compared to a placebo supplement?
Researchers will compare the tailored amino acid supplement to a placebo (a look-alike substance that contains no active ingredients) to see if the tailored amino acid supplements work to support health for people with Parkinson's disease.
Participants will:
Take the tailored amino acid supplement or a placebo every day for 6 months, visit the lab at baseline, after 3 months, and after 6 months for fasting blood draws, body composition assessment, and physical and mental health testing and keep a diary of their food intake and supplement intake.
Detailed description
The purpose of this trial is to determine the effects of a targeted amino acid supplement (T-AA) specifically designed to correct characteristic amino acid deficiencies and meet the unique nutritional needs of people with Parkinson's disease (PD) on 1) plasma amino acid (AA) bioavailability, 2) metabolic function, 3) body composition, 4) physical function and 5) self-reported outcomes.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Control | Placebo comparator | Dietary Supplement: Control (placebo)The inert amino acid (alanine) will serve as an isonitrogenous control. |
| Targeted Amino Acid Supplement | Experimental | Dietary Supplement: Targeted Amino Acid SupplementBlend of the essential amino acids (Leucine \& Tryptophan), a conditionally essential amino acids (Arginine \& Taurine), and non-essential amino acids (Glutamate \& Tyrosine) designed to meet the unique nutritional needs of people with Parkinson's disease (PD). |
Who may qualify
- Ages
- 50 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Targeted Amino Acid SupplementBlend of the essential amino acids (Leucine \& Tryptophan), a conditionally essential amino acids (Arginine \& Taurine), and non-essential amino acids (Glutamate \& Tyrosine) designed to meet the unique nutritional needs of people with Parkinson's disease (PD). | Dietary supplement | Targeted Amino Acid Supplement |
| Control (placebo)The inert amino acid (alanine) will serve as an isonitrogenous control. | Dietary supplement | Control |
Primary outcome
Amino Acid bioavailability (Lysine, Tryptophan, Arginine, Glutamate, Leucine, Taurine, Glutathione)
Time frame: Baseline, 3 months, and 6 months
Circulating amino acid concentrations will be measured from blood samples using high performance liquid chromatography using a solid phase column specifically designed to test amino acids (e.g. 00F-4435-E0, Phenomenex, USA) along with appropriate column guards (e.g. AJ0-7597 \& KJ0-4282, Phenomenex, USA) and liquid phases. This analysis will be performed at the Laboratory of Mass Spectroscopy and Omics Analysis.
Oxidative stress
Time frame: Baseline, 3 months, 6 months
Oxidative stress will be measured using a total antioxidant power test (e.g. ab65329, ABCAM, USA). It is a quantitative bioassay and will be performed using the laboratory facilities.
Oxidative stress
Time frame: Baseline, 3 months, and 6 months
Oxidative stress will be assessed with reduced/oxidized glutathione assays (e.g. ab138881, ABCAM, USA). It is a quantitative bioassay and will be assessed using laboratory facilities.
19 secondary outcomes
Body composition: Bioelectrical impedance
Time frame: Baseline, 3 months, 6 months
Body composition: Ultrasound & Shear Wave Elastography (Tissue Organization & Fibrosis)
Time frame: Baseline, 3 months, 6 months
Physical function: Physical activity
Time frame: 7 days prior to baseline visit and 7 days after the 6-month visit
Physical function: Balance (Mini Balance Evaluation System Test)
Time frame: baseline, 3 months, 6 months
Physical function: Gait speed (4-meter walking test)
Time frame: baseline, 3 months, 6 months
Physical function: Gait speed (10-meter walk test)
Time frame: baseline, 3 months, 6 months
Physical function: Functional lower extremity strength (5 Times Sit to Stand Test)
Time frame: baseline, 3 months, 6 months
Physical function: Grip strength
Time frame: baseline, 3 months, 6 months
Physical function: Maximal voluntary isometric contraction
Time frame: baseline, 3 months, 6 months
Self-reported outcome: Quality of Life (Parkinson Disease Questionnaire-39)
Time frame: baseline, 3 months, 6 months
Self-reported outcome: Fatigue (Parkinson's Fatigue Scale)
Time frame: baseline, 3 months, 6 months
Self-reported outcome: Sleep (Scales for Outcomes in Parkinson disease- Sleep, nighttime sleep)
Time frame: baseline, 3 months, 6 months
Self-reported outcome: Sleep (Scales for Outcomes in Parkinson disease- Sleep, daytime sleepiness)
Time frame: Baseline, 3 months, 6 months
Self-reported outcome: Sleep (Scales for Outcomes in PD-Sleep, Global sleep quality)
Time frame: Baseline, 3 months, 6 months
Self-reported outcome: Mood (Profile of Mood State)
Time frame: baseline, 3 months, 6 months
Self-reported outcome: Anxiety (Beck Anxiety Inventory)
Time frame: baseline, 3 months, 6 months
Self-reported outcome: Motivation (Behavioral Regulation in Exercise Questionnaire-2)
Time frame: baseline, 3 months, 6 months
Self-reported outcome: Depression (Geriatric Depression Scale-short form)
Time frame: baseline, 3 months, 6 months
Insulin sensitivity
Time frame: baseline, 3 months, 6 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Aug 2026.
- Background: PubMed 36809398Earp JE, Colon-Semenza C, LoBuono DL. Considerations for developing a targeted amino acid supplement for people with Parkinson's disease that promotes health while accounting for pathophysiology and medication interference. Nutr Rev. 2023 Jul 10;81(8):1063-1076. doi: 10.1093/nutrit/nuad008.
- Individual participant dataSharing planned: Yes. IPD used in the results publication
Related trials for Parkinson Disease (PD)
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Active, not recruitingPhase 1/2
Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease
Parkinson Disease (PD)
Active, not recruitingObservational study
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Parkinson Disease
Not yet recruiting
Evaluating the Effect of the Zeen Mobility Device on Clinical Practicality, Safety, and Impact (Via Assessments of Walking, Standing Tolerance, Balance, Endurance, Effort, and Participation in Daily Tasks) in an Outpatient Rehabilitation Setting for Individuals With Mobility Impairments.
Stroke, Parkinson's Disease (PD)
Active, not recruitingPhase 2
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
Carcinoma, Non-Small-Cell Lung
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Targeted Amino Acid Supplement in people with Parkinson Disease (PD), run by Cristina Colon-Semenza at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 13 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Carlos Rehbein, MS (860-634-8203, carlos.rehbein@uconn.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Amino Acid bioavailability (Lysine, Tryptophan, Arginine, Glutamate, Leucine, Taurine, Glutathione) (time frame: Baseline, 3 months, and 6 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07115563, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Aug 2026.